NCT02985775View on ClinicalTrials.gov

Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2019

Conditions
CMV Infection
Interventions
BIOLOGICAL

Donor-derived CMVpp65-specific T cells

About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.

Trial Locations (1)

100044

Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT02985775 - Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation | Biotech Hunter | Biotech Hunter